Editas Medicine, Inc. (EDIT) Q2 2020 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2020.
Editas Medicine
EDIT
EDIT
$34.23
-$1.85
-5.1%
Price as of August 24, 2020, 4:30 p.m. EDT
View Interactive EDIT Charts
Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
Interactive Chart
News & Analysis: Editas Medicine
The Fool has written over 100 articles on Editas Medicine.
Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today
A rumored merger has investors excited, although details are scarce.
Could Editas Medicine Be a Millionaire-Maker Stock?
It's possible. But is it probable?
2 Best Gene-Editing Stocks to Buy in July
These two cutting-edge gene-editing companies are locked in tight competition.
3 Top Biotech Stocks to Watch in July
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
Better Buy: Editas Medicine vs. Intellia
Which of these companies that are developing cutting-edge gene-editing technologies is the better buy for investors?
Why Editas Medicine Is Now the CRISPR Stock to Really Watch
It could soon be Editas' time to shine.
4 Promising Stocks to Own That You Probably Forgot About
These four companies have tremendous growth potential going into 2020.
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Editas has more favorable terms for its collaborations with big pharma companies, but it still has a long way to go.
Editas Medicine, Inc. (EDIT) Q1 2020 Earnings Call Transcript
EDIT earnings call for the period ending March 31, 2020.